Clinical Guidelines Highlights

Check box icon

AMDA recommends that most LTC residents with COPD should be treated with long-acting maintenance bronchodilators1*

AMDA recommendation

Used by permission. Further reproduction and/or distribution not permitted without written permission from AMDA. Sunovion has derived this information, with permission from AMDA, from the AMDA Clinical Practice Guideline (CPG) on COPD. Sunovion had no involvement in the preparation of the CPG.


Bronchodilators, especially the long-acting forms, are underutilized in PA/LTC. —AMDA, 2016



*AMDA–The Society for Post-Acute Care and Long-Term Medicine does not endorse any specific treatments.
From a retrospective analysis of more than 126,000 nursing home residents.

AMDA guidelines summary

AMDA recommends maintenance therapy in LTC.

Read a summary of the AMDA guidelines
 
 

AMDA does not endorse any specific treatments.
 

AMDA recommendation

Used by permission. Further reproduction and/or distribution not permitted without written permission from AMDA. Sunovion has derived this information, with permission from AMDA, from the AMDA Clinical Practice Guideline (CPG) on COPD. Sunovion had no involvement in the preparation of the CPG.


Bronchodilators, especially the long-acting forms, are underutilized in PA/LTC. —AMDA, 2016



*AMDA–The Society for Post-Acute Care and Long-Term Medicine does not endorse any specific treatments.
From a retrospective analysis of more than 126,000 nursing home residents.

AMDA guidelines summary

AMDA recommends maintenance therapy in LTC.

Read a summary of the AMDA guidelines
 
 

AMDA does not endorse any specific treatments.
 

GOLD report icon

The GOLD 2018 report recommends the use of long-acting bronchodilators for COPD maintenance therapy2

COPD patients in all groups may benefit from a long-acting bronchodilator

  • Inhaled therapy is preferred
  • Prescribe a long-acting bronchodilator for maintenance treatment, with a goal to manage symptoms
  • Use of short-acting bronchodilators for maintenance treatment is generally not recommended

ABCD assessment tool

*CAT is the intellectual property of GlaxoSmithKline. Not validated for US-based physicians.

© 2018 Global Strategy for Diagnosis, Management, and Prevention of COPD. All rights reserved. Use is by express license from the owner.


Inhalation-device education and technique training are essential to symptom management.2

On average more than two-thirds of patients make at least one error in using an inhalational device. —GOLD, 2018


GOLD does not endorse any specific treatments. The inclusion of GOLD information is not an endorsement of SEEBRI NEOHALER (indacaterol/glycopyrrolate) Inhalation Powder.

COPD=chronic obstructive pulmonary disease.
GOLD=Global Initiative for Chronic Obstructive Lung Disease.
LTC=long-term care.
PA=post-acute.

USING SEEBRI NEOHALER IN LONG-TERM CARE 

COPD patients in all groups may benefit from a long-acting bronchodilator

  • Inhaled therapy is preferred
  • Prescribe a long-acting bronchodilator for maintenance treatment, with a goal to manage symptoms
  • Use of short-acting bronchodilators for maintenance treatment is generally not recommended

ABCD assessment tool

*CAT is the intellectual property of GlaxoSmithKline. Not validated for US-based physicians.

© 2018 Global Strategy for Diagnosis, Management, and Prevention of COPD. All rights reserved. Use is by express license from the owner.


Inhalation-device education and technique training are essential to symptom management.2

On average more than two-thirds of patients make at least one error in using an inhalational device. —GOLD, 2018


GOLD does not endorse any specific treatments. The inclusion of GOLD information is not an endorsement of SEEBRI NEOHALER (indacaterol/glycopyrrolate) Inhalation Powder.

COPD=chronic obstructive pulmonary disease.
GOLD=Global Initiative for Chronic Obstructive Lung Disease.
LTC=long-term care.
PA=post-acute.

USING SEEBRI NEOHALER IN LONG-TERM CARE 


References:
1. AMDA—The Society for Post-Acute and Long-Term Care Medicine. COPD Management in the Post-Acute and Long-Term Care Setting Clinical Practice Guideline. Columbia, MD: AMDA; 2016.
2. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: 2018 report. Global Initiative for Chronic Obstructive Lung Disease (GOLD). 2018:1-123. 

Important Safety Information & Indication

Important Safety Information

SEEBRI NEOHALER is contraindicated in patients with a hypersensitivity to glycopyrrolate or to any of the ingredients.

SEEBRI NEOHALER should not be initiated in patients with acutely deteriorating or potentially life-threatening episodes of COPD or used as rescue therapy for acute episodes of bronchospasm. Acute symptoms should be treated with an inhaled short-acting beta2-agonist.

As with other inhaled medicines, SEEBRI NEOHALER can produce paradoxical bronchospasm that may be life threatening. If paradoxical bronchospasm occurs following dosing with SEEBRI NEOHALER, it should be treated immediately with an inhaled, short-acting bronchodilator; SEEBRI NEOHALER should be discontinued immediately and alternative therapy instituted.

Immediate hypersensitivity reactions have been reported with SEEBRI NEOHALER. If signs occur, discontinue immediately and institute alternative therapy. SEEBRI NEOHALER should be used with caution in patients with severe hypersensitivity to milk proteins.

SEEBRI NEOHALER should be used with caution in patients with narrow-angle glaucoma and in patients with urinary retention. Prescribers and patients should be alert for signs and symptoms of acute narrow-angle glaucoma (e.g., eye pain or discomfort, blurred vision, visual halos or colored images in association with red eyes from conjunctival congestion and corneal edema) and of urinary retention (e.g., difficulty passing urine, painful urination), especially in patients with prostatic hyperplasia or bladder-neck obstruction. Patients should be instructed to consult a physician immediately should any of these signs or symptoms develop.

The most common adverse events reported in ≥1% of patients taking SEEBRI NEOHALER, and occurring more frequently than in patients taking placebo, were upper respiratory tract infection (3.4% vs 2.3%), nasopharyngitis (2.1% vs 1.9%), oropharyngeal pain (1.8% vs 1.2%), urinary tract infection (1.4% vs 1.3%), and sinusitis (1.4% vs 0.7%).

SEEBRI capsules must not be swallowed as the intended effects on the lungs will not be obtained. SEEBRI capsules are only for oral inhalation and should only be used with the NEOHALER device.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.

For additional information, please see full Prescribing Information and Patient Information for SEEBRI NEOHALER.

Indication

SEEBRI® NEOHALER® (glycopyrrolate) is an anticholinergic indicated for the long-term, maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and/or emphysema.